List of Excipients in Branded Drug STAXYN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	STAXYN	vardenafil hydrochloride	0173-0822	ASPARTAME
GlaxoSmithKline LLC	STAXYN	vardenafil hydrochloride	0173-0822	CROSPOVIDONE
GlaxoSmithKline LLC	STAXYN	vardenafil hydrochloride	0173-0822	MAGNESIUM STEARATE
GlaxoSmithKline LLC	STAXYN	vardenafil hydrochloride	0173-0822	MANNITOL

STAXYN Excipient Strategy and Commercial Opportunities for Vardenafil Orally Disintegrating Tablets

Last updated: September 5, 2026

STAXYN is a 10 mg orally disintegrating tablet containing vardenafil hydrochloride, a phosphodiesterase-5 inhibitor for erectile dysfunction. Its commercial differentiation depends on rapid oral disintegration, water-free administration, taste control, dose uniformity, and preservation of vardenafil stability. The principal opportunity is a generic or line-extension product that reproduces the convenience profile while lowering manufacturing cost and improving palatability.

The formulation uses a conventional direct-compression orally disintegrating tablet platform. Key excipient functions include mannitol as a soluble diluent, crospovidone as a disintegrant, magnesium stearate as a lubricant, colloidal silicon dioxide as a flow aid, and aspartame and peppermint flavor for taste management. These ingredients are widely available, which reduces supply-chain risk and makes the formulation technically accessible to generic manufacturers.[1]

What is STAXYN and how does its formulation work?

STAXYN is the orally disintegrating tablet version of vardenafil hydrochloride. Each tablet contains the equivalent of 10 mg of vardenafil. The tablet is placed on the tongue, where it disintegrates without water. Patients are instructed not to remove the tablet from the blister until immediately before dosing and not to push the tablet through the foil.[1]

STAXYN product profile

Attribute	STAXYN
Active ingredient	Vardenafil hydrochloride
Strength	10 mg vardenafil equivalent
Dosage form	Orally disintegrating tablet
Route	Oral
Therapeutic class	PDE5 inhibitor
Reference product sponsor	Bayer Pharmaceuticals, with US commercial rights historically associated with Bayer and GlaxoSmithKline
FDA application	NDA 022406
Initial US approval	2010
Administration	On the tongue without water
Indication	Erectile dysfunction
Controlled substance	No

STAXYN is not a sublingual product in the pharmacological sense. The tablet disintegrates in the mouth, but vardenafil is absorbed primarily through the gastrointestinal tract. The dosage form is intended to improve convenience rather than create a fundamentally different absorption pathway.

What excipients are used in STAXYN?

The FDA-approved prescribing information identifies the following inactive ingredients: mannitol, crospovidone, magnesium stearate, colloidal silicon dioxide, aspartame, and peppermint flavor.[1]

Excipient	Primary formulation role	Commercial relevance
Mannitol	Water-soluble filler and mouthfeel modifier	Supports rapid dissolution and cooling sensation
Crospovidone	Superdisintegrant	Promotes rapid tablet breakup with limited liquid
Magnesium stearate	Lubricant	Supports tablet ejection and manufacturing efficiency
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and blend uniformity
Aspartame	Sweetener	Masks vardenafil bitterness
Peppermint flavor	Flavoring agent	Improves patient acceptability and reduces medicinal taste

The formulation does not depend on an unusual or proprietary excipient. Its technical barrier is the interaction among excipient grade, compression force, particle size, flavor distribution, moisture exposure, and taste performance.

How does the STAXYN excipient strategy support oral disintegration?

Mannitol and crospovidone form the central disintegration system. Mannitol dissolves readily in saliva and provides a relatively clean mouthfeel. Crospovidone absorbs saliva and promotes capillary action and tablet breakup. The combination avoids reliance on large amounts of hygroscopic excipients that could compromise stability.

The formulation must balance four competing properties:

1. Sufficient mechanical strength for packaging and handling.
2. Fast disintegration on the tongue.
3. Low friability during blister-packaging operations.
4. Acceptable taste after exposure to saliva.

Higher compression force generally improves hardness but can slow disintegration. Higher crospovidone levels can accelerate breakup but may increase tablet porosity, friability, or mouthfeel issues. Excess magnesium stearate can impair wetting and slow disintegration because of its hydrophobic character. These tradeoffs create room for formulation optimization without copying the exact quantitative composition of the reference product.

Why mannitol is commercially important

Mannitol is well suited to orally disintegrating tablets because it has high water solubility, low hygroscopicity relative to several alternative polyols, and a cooling oral sensation. It is also available in multiple particle-size and spray-dried grades. A generic manufacturer can select a directly compressible grade to simplify processing or a granular grade to adjust porosity and tablet strength.

Potential substitutes include lactose, xylitol, sorbitol, isomalt, and co-processed excipient systems. Each changes the product profile:

Filler option	Potential advantage	Main development concern
Mannitol	Low moisture uptake and favorable mouthfeel	Can require optimized compression for adequate hardness
Lactose	Low cost and broad availability	Possible flavor and moisture-performance limitations
Xylitol	Sweet taste and cooling effect	Hygroscopicity and stability considerations
Sorbitol	High solubility and sweetness	Greater moisture sensitivity
Isomalt	Good compressibility and mouthfeel	Higher material cost
Co-processed filler	Tailored flow and compaction	Supplier dependence and higher qualification burden

What formulation patents protect STAXYN?

STAXYN’s commercial differentiation came primarily from the orally disintegrating dosage form and its product presentation rather than from a rare excipient. The vardenafil active-ingredient patent estate and dosage-form patents were separate components of the broader exclusivity strategy.

Public patent analysis should distinguish among:

• Vardenafil compound patents.
• Pharmaceutical-composition patents.
• Orally disintegrating tablet claims.
• Taste-masking and flavor claims.
• Manufacturing-process claims.
• Product-by-process or tablet-physical-property claims.

The exact enforceability of any patent depends on claim scope, terminal disclaimers, prosecution history, maintenance fees, and litigation outcomes. The core US market opportunity is now primarily an abbreviated new drug application opportunity rather than a branded-exclusivity opportunity. FDA Orange Book status, current patent listings, and any Paragraph IV certifications must be checked against the live Orange Book and the relevant FDA approval history before a launch decision.[2]

What patent claims are most relevant to a STAXYN generic?

The highest-value claims would typically cover:

• A vardenafil orally disintegrating tablet with defined disintegration performance.
• A specific excipient combination.
• A taste-masked composition.
• A tablet containing a defined amount of mannitol and crospovidone.
• A low-moisture manufacturing process.
• A blister-packaged dosage form with defined stability characteristics.

A generic developer can reduce infringement exposure through a design-around using a different filler, alternative sweetener, different flavor system, modified compression process, or distinct granulation approach. FDA bioequivalence does not require identical excipients, subject to applicable regulatory and safety requirements.

When does STAXYN lose exclusivity and what is the generic-entry position?

STAXYN was approved in 2010, so its ordinary five-year new chemical entity exclusivity period has expired. Any pediatric exclusivity would also have expired. The commercial question is therefore not whether the product remains protected by FDA exclusivity, but whether listed patents, unlisted formulation rights, regulatory barriers, or commercial scale limit generic entry.[2]

Exclusivity category	STAXYN position
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current commercial significance
Orphan-drug exclusivity	Not applicable to the erectile-dysfunction indication
Biologic exclusivity	Not applicable
180-day generic exclusivity	Depends on any qualifying first Paragraph IV filer
Patent protection	Requires current Orange Book and patent-record review
Reference-product status	NDA reference product for ANDA strategy

What Paragraph IV challenges affect STAXYN?

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. If a current listed patent exists, the first ANDA applicant to submit a qualifying Paragraph IV certification may obtain 180 days of shared or sole generic exclusivity, depending on the statutory circumstances.[3]

For STAXYN, the commercial value of a Paragraph IV strategy is likely lower than it was during the product’s original patent term because:

• The product has an older approval date.
• Vardenafil is available in conventional tablets.
• The orally disintegrating segment is narrower than the overall PDE5 market.
• Erectile-dysfunction products face significant brand and pricing competition.
• A formulation patent challenge may require costly technical and clinical evidence.

The strongest target would be a narrow, still-listed formulation patent with meaningful market coverage and no readily available design-around.

What FDA regulatory pathway applies to a STAXYN generic?

A generic STAXYN product would normally be submitted through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, along with appropriate controls for identity, strength, quality, purity, and stability.[4]

Key development requirements

The principal development package would include:

• Comparative dissolution testing.
• In vitro disintegration testing.
• Assay and content uniformity.
• Impurity and degradation-product control.
• Stability under long-term and accelerated conditions.
• Packaging qualification.
• Bioequivalence studies where required.
• Excipient safety justification.
• Demonstration of acceptable tablet handling and dose delivery.

The major technical question is whether FDA would require a clinical pharmacokinetic study, a pharmacodynamic study, or another comparative approach for the specific product. The answer depends on the current reference-product status, FDA product-specific guidance, and the proposed formulation.

What manufacturing and IP barriers exist for STAXYN?

Manufacturing barriers are moderate rather than fundamental. The active ingredient is commercially established, and the excipients are standard pharmaceutical materials. The main process risks are:

• Segregation of low-dose vardenafil during blending.
• Flavor loss or uneven flavor distribution.
• Over-lubrication with magnesium stearate.
• Tablet capping or friability at low compression force.
• Moisture uptake during manufacturing.
• Blister seal integrity.
• Stability changes caused by flavor or sweetener degradation.

A direct-compression process offers the lowest capital requirement. Wet granulation can improve blend uniformity but adds moisture and drying steps. Dry granulation can improve flow while limiting water exposure, but it may alter porosity and disintegration.

Aluminum-aluminum blister packaging is commercially attractive because it limits moisture and light exposure. Packaging selection is part of the formulation strategy, not a secondary decision. A lower-cost high-barrier blister may allow a less complex excipient system, while a weaker package can force tighter moisture specifications and shorter shelf-life targets.

What commercial opportunities exist for STAXYN excipients?

The best opportunities are differentiated generic products and regional line extensions, not new chemical entities.

Generic orally disintegrating tablets

A manufacturer can compete through:

• Lower-cost mannitol grades.
• Improved taste masking.
• Faster disintegration.
• Smaller tablet size.
• More robust blister packaging.
• Lower manufacturing waste.
• A distinct flavor profile.
• A formulation that avoids aspartame for patients who prefer or require alternative sweeteners.

Aspartame-free products

Aspartame provides sweetness but contains phenylalanine. The STAXYN label warns patients with phenylketonuria that the product contains phenylalanine.[1] An aspartame-free product could target institutional formularies, consumer preference, and patients seeking alternative sweetener systems.

Possible alternatives include sucralose, acesulfame potassium, saccharin, steviol glycosides, or sugar alcohol combinations. Each requires evaluation for bitterness, aftertaste, moisture behavior, and compatibility with the tablet matrix.

Pediatric-style and geriatric-friendly design

STAXYN is indicated for adults, but the dosage-form technology has broader platform value. The same excipient architecture can support orally disintegrating products for patients with difficulty swallowing, provided the active ingredient and indication are appropriate. A developer could use the platform for other PDE5 inhibitors or unrelated compounds with strong taste and low-dose uniformity challenges.

Contract development and manufacturing

CDMOs with expertise in orally disintegrating tablets can offer a complete package covering:

• Excipient screening.
• Taste-masking development.
• Direct compression.
• Blister packaging.
• Stability studies.
• Comparative dissolution.
• ANDA support.

The highest-value capability is rapid optimization of tablet hardness, disintegration, and palatability without requiring a new proprietary excipient.

How does STAXYN compare with Viagra and Levitra?

Product	Active ingredient	Dosage-form differentiation	Excipient opportunity
STAXYN	Vardenafil	Orally disintegrating tablet	Taste masking, fast disintegration, water-free dosing
Levitra	Vardenafil	Conventional film-coated tablet	Lower manufacturing complexity but less differentiated convenience
Viagra	Sildenafil	Conventional film-coated tablet and other presentations	Larger generic competition and broader supply base
Cialis	Tadalafil	Conventional tablet	Longer duration creates stronger therapeutic differentiation than dosage form

STAXYN’s competitive advantage is convenience, not superior PDE5 pharmacology. Its excipient strategy must therefore protect the patient experience at a cost that supports generic pricing.

What is the revenue exposure and launch potential?

Revenue exposure is limited relative to the leading PDE5 brands because the product addresses a narrower dosage-form segment. The commercial opportunity improves in markets where:

• Water-free dosing has meaningful patient value.
• Vardenafil remains reimbursed.
• The reference product has limited availability.
• Generic substitution is permitted.
• Blister-packaged products command a price premium.
• Erectile-dysfunction treatment is primarily cash-pay rather than formulary-driven.

A generic launch could follow three paths:

Launch scenario	Commercial profile
Price-led generic	Fast access, limited differentiation, lower gross margin
Premium convenience generic	Higher price justified by taste, packaging, and patient experience
Regional license or co-brand	Lower development cost with limited geographic scope

Licensing opportunities are most credible for companies with an established PDE5 portfolio, a regional commercial network, or an ODT manufacturing platform. The asset is more attractive as a portfolio extension than as a standalone global launch.

What geographic coverage matters for STAXYN?

The United States requires Orange Book and ANDA analysis. Europe and other jurisdictions require separate review of national or regional patent rights, supplementary protection certificates, marketing authorizations, and local generic-substitution rules. A US formulation strategy does not automatically establish freedom to operate elsewhere.

The strongest geographic opportunity is likely in markets where:

• Vardenafil is approved but STAXYN-style ODT supply is limited.
• Patients pay directly for erectile-dysfunction medicines.
• Local packaging and flavor adaptation are permitted.
• A regional partner can manage registration and distribution.

Key Takeaways

• STAXYN is a vardenafil 10 mg orally disintegrating tablet approved in the United States in 2010.
• Its principal excipients are mannitol, crospovidone, magnesium stearate, colloidal silicon dioxide, aspartame, and peppermint flavor.
• The formulation’s technical value lies in the balance among rapid disintegration, tablet strength, palatability, moisture control, and packaging.
• The core excipients are widely available, so the main barriers are process control, taste performance, stability, and regulatory execution.
• A generic developer can pursue an ANDA with a redesigned excipient system, including an aspartame-free formulation.
• Patent analysis should separate vardenafil compound rights from ODT, taste-masking, process, and packaging claims.
• The most credible commercial opportunity is a differentiated generic or regional license, not a new chemical entity program.
• Blister packaging and excipient selection should be developed together because moisture protection directly affects shelf life and formulation flexibility.

FAQs

Can mannitol be replaced in a STAXYN generic?

Yes. Lactose, xylitol, sorbitol, isomalt, and co-processed fillers are potential alternatives. The replacement must preserve disintegration, hardness, mouthfeel, stability, and bioequivalence.

Does STAXYN require refrigeration?

The product is generally stored at controlled room temperature in its original package. The applicable storage condition must be confirmed against the current approved labeling and proposed generic stability data.[1]

Is STAXYN suitable for patients with phenylketonuria?

The product contains aspartame, which is a source of phenylalanine. The FDA label includes a warning for patients with phenylketonuria.[1]

Can a generic STAXYN tablet use a different flavor?

Yes. A different flavor is possible if the product remains pharmaceutically equivalent, meets quality requirements, and provides acceptable taste and stability.

Is STAXYN a biosimilar opportunity?

No. Vardenafil is a small-molecule drug. The relevant pathway is an ANDA or, depending on the product and regulatory strategy, another small-molecule application pathway. Biosimilar rules do not apply.

References

1. U.S. Food and Drug Administration. (2011). Staxyn (vardenafil hydrochloride) orally disintegrating tablets: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Paragraph IV drug product applications: 180-day exclusivity. FDA.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. FDA.